View Clinical Trial (Medical Research Study)
Investigation Into Effects Upon Counterregulatory Responses to Hypoglycemia During Intensive Treatment of Insulin-dependent Diabetes Mellitus.
| City: |
|
New Haven |
| State: |
|
Connecticut |
| Zip Code: |
|
06520 |
| Conditions: |
|
Type 1 Diabetes - Hypoglycemia |
| Purpose: |
|
This study is designed to investigate the effects of diabetes mellitus and its treatment
upon the body's responses to low blood glucose (blood sugar) levels. Diabetes is a medical
condition in which blood glucose can rise very high. Treatment of diabetes mellitus involves
giving insulin (a hormone), which can occasionally cause blood glucose to fall too low. The
body responds to low glucose levels by producing a number of hormones, which act against the
insulin to help correct the low blood glucose. These hormones also provide symptoms which
warn that the glucose is falling too far. These protective warnings by the body may be
different in people with diabetes. We want to test whether this also means that diabetes
changes the sensitivity of brain function to a lowering of blood glucose levels. In order to
answer this question, we need to compare the response of people with diabetes with the
response of people who do not have diabetes.
The plan of the study is to lower the subject's blood glucose using insulin, while measuring
what changes occur in brain function using what is called functional magnetic resonance
imaging (fMRI).
|
| Study Summary: |
|
Previous studies have shown that a person with type 1 diabetes is less likely to suffer the
long term microvascular complications of diabetes (eye, kidney and nerve damage) if they
strive to achieve as near normal a blood glucose as possible. Unfortunately the tighter the
blood glucose control is, the more likely the subject is to suffer episodes of hypoglycemia.
Hypoglycemia is often the aspect of diabetes management most feared by people with diabetes
and may cause more anxiety than the threat of advanced complications.
For many people with diabetes the problem of hypoglycemia is compounded by the development
of the syndrome of hypoglycemia unawareness. One aspect of hypoglycemia unawareness is
impairment of the hormones normally released as blood glucose falls. Hypoglycemia triggers a
release of such insulin antagonists as epinephrine, norepinephrine, glucagon, growth hormone
and cortisol. These hormones act synergistically with the autonomic nervous system to raise
blood glucose, counteracting insulin and restoring normoglycemia. These homeostatic
mechanisms are also responsible for some of the early symptoms of low blood glucose,
providing a warning to insulin-treated diabetics as glucose falls. A number of studies
including research from this unit have established that strict metabolic control is
associated with impairment of the normal counterregulatory response to hypoglycemia and a
loss of hypoglycemia awareness.
The brain is central to the recognition of hypoglycemia and the coordination of the
counterregulatory response. Neural tissue depends mainly on glucose for its energy supply.
As circulating glucose falls beneath the level needed to maintain glucose transport across
the blood-brain barrier, a variety of defense mechanisms are activated, including symptoms
of cognitive dysfunction. However, the precise nature and causes of the adverse CNS effects
of hypoglycemia are not well understood.
Functional magnetic resonance imaging (fMRI) provides a tool to measure the effects of
hypoglycemia on the patterns and magnitudes of neuronal activation in the human brain, in
both normal and diabetic subjects.
|
| Criteria: |
|
Inclusion Criteria:
- All subjects:
- on a weight maintaining diet
- ability to read and speak English fluently
- For All Type 1 Diabetics all of the above inclusion criteria AND C-peptide negative
AND no evidence of neuropathy or proliferative retinopathy
- Only for Type 1 Diabetics in the intensively treated group: HbA1c < 7.5% AND
documented hypoglycemia at least once per week over at least 4 weeks of frequent
daily self monitoring
- Only for Type 1 Diabetics in the conventionally treated group:HbA1c ≥ 8.5%
- Age 18-40 years in the groups 1,2, and 3. Age 18-50 in groups arm 2 obese and
control.
- BMI <30 in the groups 1,2, and 3; BMI >18.4 but < or = 25 in the arm control group;
and BMI > or = 30kg/m2 in the obese group.
Exclusion Criteria:
- Pregnancy
- History of neurologic or cardiovascular disease
|
| NCT ID: |
|
NCT00580710 |
| Primary Contact: |
|
Principal Investigator
Robert Sherwin, M.D.
Yale University
Renata D Belfort-DeAguiar, MD
Phone: 203 785 6222
Email: glucose.studies@yale.edu
|
| Backup Contact: |
|
Email: glucose.studies@yale.edu
Sarita Naik, MD
Phone: 203 785 6222
|
| Location Contact: |
|
New Haven, Connecticut 06520
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|